Agios Pharmaceuticals Inc (NASDAQ: AGIO) is -3.16% lower on its value in year-to-date trading and has touched a low of $20.96 and a high of $62.58 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AGIO stock was last observed hovering at around $33.28 in the last trading session, with the day’s loss setting it -1.46%.
Currently trading at $31.82, the stock is -7.92% and -30.80% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.0 million and changing -4.39% at the moment leaves the stock -25.08% off its SMA200. AGIO registered 45.03% gain for a year compared to 6-month loss of -32.53%. The firm has a 50-day simple moving average (SMA 50) of $46.2436 and a 200-day simple moving average (SMA200) of $42.45465.
The stock witnessed a -18.34% gain in the last 1 month and extending the period to 3 months gives it a -24.31%, and is -11.36% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.97% over the week and 6.13% over the month.
Agios Pharmaceuticals Inc (AGIO) has around 383 employees, a market worth around $1.81B and $32.87M in sales. Current P/E ratio is 2.80. Profit margin for the company is 2051.38%. Distance from 52-week low is 51.81% and -49.15% from its 52-week high. The company has generated returns on investments over the last 12 months (40.35%).
with sales reaching $9.35M over the same period.The EPS is expected to grow by 280.76% this year, but quarterly earnings will post 31.10% year-over-year. Quarterly sales are estimated to grow 31.60% in year-over-year returns.
306.0 institutions hold shares in Agios Pharmaceuticals Inc (AGIO), with institutional investors hold 108.00% of the company’s shares. The shares outstanding are 57.02M, and float is at 55.13M with Short Float at 10.02%. Institutions hold 106.37% of the Float.
The top institutional shareholder in the company is FARALLON CAPITAL MANAGEMENT LLC with over 5.65 million shares valued at $243.82 million. The investor’s holdings represent 9.9547 of the AGIO Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 5.5 million shares valued at $237.02 million to account for 9.6769 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 4.86 million shares representing 8.5542 and valued at over $209.52 million, while BELLEVUE GROUP AG holds 6.8299 of the shares totaling 3.88 million with a market value of $167.29 million.
Agios Pharmaceuticals Inc (AGIO) Insider Activity
The most recent transaction is an insider sale by Milanova Tsveta, the company’s Chief Commercial Officer. SEC filings show that Milanova Tsveta sold 2,804 shares of the company’s common stock on Jan 06 ’25 at a price of $32.18 per share for a total of $90233.0. Following the sale, the insider now owns 18906.0 shares.
Still, SEC filings show that on Dec 11 ’24, Scadden David (Director) disposed off 200 shares at an average price of $46.28 for $9256.0. The insider now directly holds 15,483 shares of Agios Pharmaceuticals Inc (AGIO).
